Teerenpeli From Finland is the Best Whisky Producer in the World 2020
8.12.2020 16:43:00 EET | Business Wire | Press release
Lahti-based Teerenpeli Brewery & Distillery has been awarded as the “Worldwide whisky producer” in one of the world’s largest alcohol competitions, the International Wine and Spirit Competition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005705/en/
Lahti-based Teerenpeli Brewery and Distillery has been awarded as the “Worldwide whisky producer” in one of the world’s largest alcohol competitions, the International Wine and Spirit Competition. Photo by Teerenpeli.
Hundreds of distilleries from around the world took part in the international competition in London. Four skillful producers were invited to the final round as a nominee for the Best Worldwide Whisky Producer 2020. The nominees with Teerenpeli this year were Kavalan Distillery from Taiwan, Sazerac Company from the United States, and The Lark Distillery from Australia in the category for Scotch Whisky producers.
“It was a great honor for us to receive the first candidacy in Finland. But the fact that we won the series is, of course, a tremendous recognition of almost 20 years of work”, says Mr. Samuli Korhonen, General Manager of Teerenpeli Brewery & Distillery.
Mr. Anssi Pyysing, Entrepreneur and CEO of Teerenpeli, considers the victory a big surprise but he also sees many good reasons for it. “The location of Teerenpeli Distillery is perfect for whisky-making. The groundwater filtered by the Salpausselkä ridges is the best in the world. Barley is grown in local fields and after harvesting, it is malted in the town of Lahti just next to Teerenpeli Distillery. On top of that adding all the experience, skill, and passion of the excellent staff at Teerenpeli, you end up being the best in the world.”
The IWSC awarded Teerenpeli Distillery whiskies with top mentions in the summer. The Whisky Producer of the Year award completed Teerenpeli's rise as a world-class whisky maker, Korhonen describes.
This year, Teerenpeli signed new export agreements in Belgium, Luxembourg and the Netherlands. Whisky exporting to Germany and Sweden is also increasing, and an agreement with a Swedish importing company is going to take Teerenpeli Kaski whisky to Systembolaget stores as the first Finnish whisky.
Teerenpeli Group is a family business owned by Anssi and Marianne Pyysing. Company runs whisky distillery and brewery in Lahti, Finland and ten restaurants all over Finland. Teerenpeli Group was established in 1994 and employs more than 100 people.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005705/en/
Contact information
Samuli Korhonen, General Manager
Teerenpeli Brewery & Distillery
+358 40 861 1081
samuli.korhonen@teerenpeli.com
Anssi Pyysing, CEO, entrepreneur
Teerenpeli Group
+358 500 830 458
anssi.pyysing@teerenpeli.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom